Causes of hospital readmissions after urologic cancer surgery.

[1]  Jeanette W. Chung,et al.  Underlying reasons associated with hospital readmission following surgery in the United States. , 2015, JAMA.

[2]  Steven L. Chang,et al.  Readmissions after major urologic cancer surgery. , 2014, The Canadian journal of urology.

[3]  Steven L. Chang,et al.  Short-term perioperative outcomes of patients treated with radical cystectomy for bladder cancer included in the National Surgical Quality Improvement Program (NSQIP) database. , 2014, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

[4]  Francesco Montorsi,et al.  Effect of minimally invasive surgery on the risk for surgical site infections: results from the National Surgical Quality Improvement Program (NSQIP) Database. , 2014, JAMA surgery.

[5]  A. Neugut,et al.  Nationwide practice patterns for the use of venous thromboembolism prophylaxis among men undergoing radical prostatectomy , 2014, World Journal of Urology.

[6]  M. Humphreys,et al.  Venous thromboembolism after urological surgery. , 2014, The Journal of urology.

[7]  T. Pawlik,et al.  Avoiding immortal time bias in the American College of Surgeons National Surgical Quality Improvement Program readmission measure. , 2014, JAMA surgery.

[8]  V. Laudone,et al.  A randomized trial of robot-assisted laparoscopic radical cystectomy. , 2014, The New England journal of medicine.

[9]  Pierre I Karakiewicz,et al.  Morbidity and mortality after benign prostatic hyperplasia surgery: data from the American College of Surgeons national surgical quality improvement program. , 2014, Journal of endourology.

[10]  Kathleen Carey,et al.  Measuring the hospital length of stay/readmission cost trade-off under a bundled payment mechanism. , 2014, Health economics.

[11]  Jonathan E. Helm,et al.  Sharpening the focus on causes and timing of readmission after radical cystectomy for bladder cancer , 2014, Cancer.

[12]  David C. Miller,et al.  Population level assessment of hospital based outcomes following laparoscopic versus open partial nephrectomy during the adoption of minimally invasive surgery. , 2014, The Journal of urology.

[13]  C. Amling,et al.  Timing, incidence and risk factors for venous thromboembolism in patients undergoing radical cystectomy for malignancy: a case for extended duration pharmacological prophylaxis. , 2014, The Journal of urology.

[14]  Mani Menon,et al.  Practice patterns and outcomes of open and minimally invasive partial nephrectomy since the introduction of robotic partial nephrectomy: results from the nationwide inpatient sample. , 2014, The Journal of urology.

[15]  R. Nadler,et al.  National multi-institutional comparison of 30-day postoperative complication and readmission rates between open retropubic radical prostatectomy and robot-assisted laparoscopic prostatectomy using NSQIP. , 2014, Journal of endourology.

[16]  K. Lassen,et al.  Enhanced recovery after surgery: are we ready, and can we afford not to implement these pathways for patients undergoing radical cystectomy? , 2014, European urology.

[17]  K. Devarajan,et al.  Familiarity and self-reported compliance with American Urological Association best practice recommendations for use of thromboembolic prophylaxis among American Urological Association members. , 2013, The Journal of urology.

[18]  S. Lipsitz,et al.  Comparative effectiveness, costs and trends in treatment of small renal masses from 2005 to 2007 , 2013, BJU international.

[19]  M. Cooperberg,et al.  Primary treatments for clinically localised prostate cancer: a comprehensive lifetime cost‐utility analysis , 2013, BJU international.

[20]  L. Holmberg,et al.  Thromboembolic events following surgery for prostate cancer. , 2013, European urology.

[21]  Ashish K. Jha,et al.  Characteristics of hospitals receiving penalties under the Hospital Readmissions Reduction Program. , 2013, JAMA.

[22]  Jens Hansen,et al.  Perioperative outcomes of robot-assisted radical prostatectomy compared with open radical prostatectomy: results from the nationwide inpatient sample. , 2012, European urology.

[23]  Michael K Gould,et al.  Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.

[24]  Elie A Akl,et al.  Prevention of VTE in Nonsurgical Patients Antithrombotic Therapy and Prevention of Thrombosis , 9 th ed : American College of Chest Physicians Evidence-Based Clinical Practice Guidelines , 2013 .

[25]  P. Austin,et al.  Proportion of hospital readmissions deemed avoidable: a systematic review , 2011, Canadian Medical Association Journal.

[26]  Sanjay G. Patel,et al.  Early and late perioperative outcomes following radical cystectomy: 90-day readmissions, morbidity and mortality in a contemporary series. , 2010, The Journal of urology.

[27]  Mark V. Williams,et al.  Rehospitalizations among patients in the Medicare fee-for-service program. , 2009, The New England journal of medicine.

[28]  R. Leveillee,et al.  AUA Best Practice Statement for the prevention of deep vein thrombosis in patients undergoing urologic surgery. , 2009, The Journal of urology.

[29]  L. Jørgensen,et al.  Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery. , 2009, The Cochrane database of systematic reviews.

[30]  Sung-joon Min,et al.  The care transitions intervention: results of a randomized controlled trial. , 2006, Archives of internal medicine.

[31]  M. Menon,et al.  Robotic radical prostatectomy: evolution from conventional to VIP , 2006, World Journal of Urology.

[32]  D. Quinlan,et al.  Thromboprophylaxis for radical prostatectomy: A comparative analysis of present practice between the USA, the UK, and Ireland , 2004, The Prostate.

[33]  G. de Lissovoy,et al.  Management of acute proximal deep vein thrombosis: pharmacoeconomic evaluation of outpatient treatment with enoxaparin vs inpatient treatment with unfractionated heparin. , 2002, Chest.

[34]  A. Cohen,et al.  Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. , 2002, The New England journal of medicine.